Focal Seals its Fate
Investors in biomedical stocks are a tough crowd. They want to see current revenue streams and a pipeline of large-market products. Unfortunately, surgical sealant developer Focal Inc. provided neither to a sufficient degree. In early May, Focal agreed to merge into Genzyme Biosurgery in a stock swap transaction. The modest purchase price of $12 million bears witness to the fact that Focal simply did not do a good job of making the transition from a technology developer to a product manufacturer, at least not in the timeframe of investors.
You may also be interested in...
Surgical sealants have promise, but can a host of companies convince surgeons that these adjunctive therapies are "need to have" not "nice to have" technologies?
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.